An Open-label, Multi-centre, Single-dose Clinical Trial to Assess the Pharmacokinetic (PK) Properties and Tolerability of a Single Oromucosal Dose of 6 Sprays of Sativex in Patients With Advanced Cancer Currently on Background Step III Opioid Therapy

Trial Profile

An Open-label, Multi-centre, Single-dose Clinical Trial to Assess the Pharmacokinetic (PK) Properties and Tolerability of a Single Oromucosal Dose of 6 Sprays of Sativex in Patients With Advanced Cancer Currently on Background Step III Opioid Therapy

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 04 Mar 2016

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Cancer pain
  • Focus Pharmacokinetics
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 01 Mar 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 08 Jun 2015 Planned End Date changed from 1 May 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
    • 08 Jun 2015 Planned primary completion date changed from 1 May 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top